Anti-CAIX CAR-T cell therapy and LB100 combination therapy significantly increased tumor-infiltrating lymphocytes (P < 0.05) and prolonged survival (P < 0.001) in xenograft U251-Luc GBM mice. This evidence concerns the gene CA9 and neoplasm.